Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioBundle, IPOs grind to a halt

BioBundle, IPOs grind to a halt

By Karen Bernstein Editor-in-ChiefFinancial fallout from the disappointing Phase III data from Synergen Inc.'s Antril sepsis drug was not long in coming, leading to the postponement last week of the Robertson, Stephens & Co. Biobundle and several IPOs.

The Antril news culminated a string of product disappointments in the past year, including two other sepsis drugs developed by Centocor Inc. and Xoma Corp. as well as chemoprotectives developed by U.S. Bioscience Inc. and MGI Pharma Inc. Coming amid hostile statements on drug pricing from Washington, the news shut down

Read the full 970 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE